KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday

KALA BIO (NASDAQ:KALA) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect KALA BIO to post earnings of ($0.32) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

KALA BIO Trading Down 1.7%

KALA stock opened at $0.23 on Tuesday. The firm has a 50 day moving average of $0.42 and a 200-day moving average of $2.58. The company has a market cap of $212.07 million, a price-to-earnings ratio of -0.04 and a beta of -2.37. KALA BIO has a 12-month low of $0.22 and a 12-month high of $20.60.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of KALA BIO in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $20.38.

Hedge Funds Weigh In On KALA BIO

Several hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP acquired a new position in KALA BIO during the first quarter worth about $1,483,000. Geode Capital Management LLC increased its stake in shares of KALA BIO by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock worth $268,000 after purchasing an additional 1,534 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of KALA BIO during the 2nd quarter worth approximately $62,000. Jane Street Group LLC acquired a new position in shares of KALA BIO during the 4th quarter worth approximately $80,000. Finally, Virtu Financial LLC acquired a new position in shares of KALA BIO during the 4th quarter worth approximately $48,000. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

About KALA BIO

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.